细胞毒性T淋巴细胞相关抗原4(CTLA-4)与肺癌的研究进展

被引：9

作者：

陈赫

赵玉霞

机构：

[1] 中国医科大学附属第四医院

来源：

现代肿瘤医学 | 2017年 / 25卷 / 04期

关键词：

细胞毒性T淋巴细胞相关抗原4; 肺癌; 研究进展;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100214 ;

摘要：

细胞毒性T淋巴细胞相关抗原4(cytotoxic T lymphocyte associated antigen-4,CTLA-4)是一种跨膜蛋白质,能够抑制T细胞的增殖与活化,降低机体抗肿瘤免疫反应。CTLA-4与多种肿瘤的形成相关,其与肺癌的内在联系也备受关注。同时在肺癌的免疫治疗中CTLA-4也扮演着重要的角色。本文就近年来CTLA-4与肺癌的研究进展进行综述。

引用

页码：645 / 650

页数：6

共 19 条

[1] Inflammation and cancer [J].

Eiro, Noemi ;

Vizoso, Francisco J. .

WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2012, 4 (03) :62-72

[2]

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study[J] . Scott Antonia,Sarah B Goldberg,Ani Balmanoukian,Jamie E Chaft,Rachel E Sanborn,Ashok Gupta,Rajesh Narwal,Keith Steele,Yu Gu,Joyson J Karakunnel,Naiyer A Rizvi.The Lancet Oncology . 2016 (3)

[3]

Cancer statistics in China, 2015[J] . Wanqing Chen,Rongshou Zheng,Peter D. Baade,Siwei Zhang,Hongmei Zeng,Freddie Bray,Ahmedin Jemal,Xue Qin Yu,Jie He.CA: A Cancer Journal for Clinicians . 2016 (2)

[4]

The role of the immune system in cancer: From mechanisms to clinical applications[J] . Michele De Palma.BBA - Reviews on Cancer . 2016 (1)

[5]

Immune-Related Adverse Events with Immune Checkpoint Blockade;a Comprehensive Review[J] . J.M. Michot,C. Bigenwald,S. Champiat,M. Collins,F. Carbonnel,S. Postel-Vinay,A. Berdelou,A. Varga,R. Bahleda,A. Hollebecque,C. Massard,A. Fuerea,V. Ribrag,A. Gazzah,J.P. Armand,N. Amellal,E. Angevin,N. Noel,C. Boutros,C. Mateus,C. Robert,J.C. Soria,A. Marabelle,O. Lambotte.European Journal of Cancer . 2015

[6]

Increased lung cancer mortality rates in the Chinese population from 1973‐1975 to 2004‐2005: An adverse health effect from exposure to smoking[J] . Xiu-Yi Zhi,Xiao‐Nong Zou,Mu Hu,Yuan Jiang,Man‐Man Jia,Gong‐Huan Yang.Cancer . 2015 (S17)

[7]

Confusing signals: recent progress in CTLA-4 biology[J] . Lucy S.K. Walker,David M. Sansom.Trends in Immunology . 2014

[8]

Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease[J] . Lawrence Steinman.Eur. J. Immunol. . 2014 (11)

[9] Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies [J].

Shih, Kent ;

Arkenau, Hendrik-Tobias ;

Infante, Jeffrey R. .

DRUGS, 2014, 74 (17) :1993-2013

[10]

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial[J] . Eugene D Kwon,Charles G Drake,Howard I Scher,Karim Fizazi,Alberto Bossi,Alfons J M van den Eertwegh,Michael Krainer,Nadine Houede,Ricardo Santos,Hakim Mahammedi,Siobhan Ng,Michele Maio,Fabio A Franke,Santhanam Sundar,Neeraj Agarwal,Andries M Bergman,Tudor E Ciuleanu,E

← 1 2 →